- Molecular NameCapreomycin
- SynonymCapastat; Capastat sulfate; Capreomycin; Capreomycin sulfate; Capreomycin sulphate
- Weight668.717
- Drugbank_IDDB00314
- ACS_NO11003-38-6
- Show 3D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)-8.47
- pkaN/A
- LogD (pH=7, predicted)-14.23
- Solubility (experiment)Soluble
- LogS (predicted, ACD/Labs)(ph=7)0.17
- LogSw (predicted, AB/LogsW2.0)537114.0
- Sw (mg/ml) (predicted, ACD/Labs)1000.0
- No.of HBond Donors19
- No.of HBond Acceptors22
- No.of Rotatable Bonds10
- TPSA378.42
- StatusFDA approved
- AdministrationN/A
- PharmacologyA peptide antibiotic, commonly grouped with the aminoglycosides, which is given in combination with other antibiotics for tuberculosis.
- Absorption_value50.0
- Absorption (description)Capreomycin is poorly absorbed after oral administration (less than 1%).
- Caco_2N/A
- Bioavailability1.0
- Protein bindingN/A
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmPaper chromatographic studies indicated that capreomycin is excreted essentially unaltered.
- Half life4~6 h
- ExcretionAbout 50% of a dose is excreted unchanged in urine by glomerular filtration within 12 h. Small amounts are excreted in bile. It is removed by haemodialysis.
- Urinary ExcretionN/A
- Clerance57 ml/h/kg.
- ToxicityOto- and nephrotoxicity are the most important adverse events in patients received Capreomycin. Hypokalemia, hypocalcemia, hypomagnesemia, and an electrolyte disturbance resembling Bartter's syndrome, pain at the injection side, tinnitus, vertigo have also been reported.
- LD50 (rat)N/A
- LD50 (mouse)N/A